JMP Securities Reiterates Market Outperform Rating for Precigen (NASDAQ:PGEN)

JMP Securities reiterated their market outperform rating on shares of Precigen (NASDAQ:PGEN) in a research report sent to investors on Tuesday morning,Benzinga reports. JMP Securities currently has a $5.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Precigen in a report on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.33.

Precigen Trading Up 1.4 %

Shares of NASDAQ PGEN opened at $1.09 on Tuesday. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The firm has a 50-day moving average of $0.90 and a two-hundred day moving average of $1.08. The company has a market capitalization of $317.76 million, a price-to-earnings ratio of -1.97 and a beta of 1.65.

Hedge Funds Weigh In On Precigen

A number of institutional investors have recently bought and sold shares of the stock. Traphagen Investment Advisors LLC purchased a new stake in Precigen during the third quarter valued at about $29,000. Stifel Financial Corp raised its holdings in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares during the period. SG Americas Securities LLC lifted its position in shares of Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 25,681 shares during the period. Finally, AQR Capital Management LLC grew its position in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.